Prana Biotechnology Limited (PBT)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!

General Information
Company Name: Prana Biotechnology Limited
Stock Code: PBT
GICS Sub-Industry: Biotechnology
Market Cap ($M): 90
Equiv. Shares (M): 489

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
$ 0.185 $ 0.190 $ 0.190 $ 0.185 $ 0.185 99,999 0%

Company Overview

Business Description:
Prana Biotechnology Limited (PBT) is an Australian biotechnology company with a focus on the development of pharmaceutical products designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses Potential applications for PBT’s MPAC (Metal-Protein Attenuating Compound) technology including Alzheimer’s, Parkinson’s and Huntington’s diseases and brain cancer.

Strategy Analysis:
The Company's focus is the development of the disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's disease. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration. Prana's lead compound PBT2 has completed Phase IIa clinical trial in patients with early Alzheimer's Disease. Planning is currently underway for a Phase IIb clinical trial of PBT2 in patients with mild to moderate Alzheimer's Disease. Prana is currently validating candidate leads from its MPAC library in the selection of PBT3 and PBT4 series compounds to be designated as follow ups of PBT2 in AD, or for use in secondary alternative indications..

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -13.3 -3.1 -- 0.0 0.0 0.0 --
2013  A -7.8 -2.3 -- 0.0 0.0 0.0 --
2012  A -5.2 -1.8 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Bionomics (BNO) $205 M -- 6.3117 0.3108 63.6364 8.7034 6.6396 0.00 0.00 0.00
CSL (CSL) $38,411 M 0.0899 0.2412 0.0806 28.3054 22.8057 21.1046 1.48 1.78 1.98
Mesoblast (MSB) $1,370 M -- -- -- -- -- -- 0.00 0.00 0.00
Prana Biotech (PBT) $95 M -- -- -- -- -- -- 0.00 -- --
Sirtex Medical (SRX) $1,506 M 0.2906 0.5153 0.3536 64.5036 42.5695 31.4485 0.53 0.65 1.05

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
PBT -- -- 2.40 -- --
Market 1.13 13.6 1.00 1.01 3.00
Sector 0.82 17.3 2.58 1.25 7.17

Name Position Start Date
Mr Geoffrey Paul Kempler Executive Director,Chief Executive Officer,Executive Chairman 11 November 1997
Mr Brian Derek Meltzer Non-Executive Director 09 December 1999
Dr George William Mihaly Non-Executive Director 09 December 1999
Mr Peter Marks Non-Executive Director 29 July 2005
Mr Lawrence Gozlan Non-Executive Director 08 August 2011
Professor Ira Shoulson Non-Executive Director 13 May 2014

Name Position
Dianne Angus Chief Operating Officer
Kathryn Andrews Company Secretary

Calendar of Events
Date Event
03 November 2015 Report (Annual)
29 September 2015 Report (Annual)
28 August 2015 Report (Prelim)
25 February 2015 Report (Interim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing and Trading in US Shares

An educational booklet that shows how to use international share trading to diversify your investments.

More details...


Australian Share Market - Close Up

CMC Markets 11/11/2014 | The Australian share market is in a decision zone - and trading from here may set the direction for the rest of the year.

Prices slashed - everything must go!

Nick Swales, Regional Director, Newcastle Office, Rathbones 27/10/2014 | “If you want to have a better performance than the crowd, you must do things differently from the crowd.” Sir John Templeton.

Aussie share market bulls now have company

Ric Spooner (Chief Market Analyst, CMC Markets) 20/10/2014 | Today, Australian investors will not have to go it alone buying stocks as they did for much of last week. Bargain hunters this morning will be supported by the morale boosting encouragement of a 3% turnaround in the German Dax and a 264 point rally in the Dow Jones.

The Importance of Ignoring the Noise of the Market

Carl Richards, director of investor education at the BAM Alliance 17/10/2014 | “As odd as it may sound, the sooner you start treating your investments like you treat life, the happier you’ll be with the outcome.”

You only dance twice

William H. Gross, Janus Capital Group 16/10/2014 | “Financial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding “minus” 10 basis points.”

The Big Picture - Australia 200 Index

CMC Markets 8/10/2014 | Share market indices around the globe are breaking down. While analysts cast around for reasons, it’s clear that a time factor is in play. Simply put, many investors “feel” a correction is overdue. How low could it go?


Sponsored Links